Profound Medical (PROF) Cash & Equivalents (2018 - 2026)

Profound Medical's Cash & Equivalents history runs 9 years deep, the most recent figure standing at $50.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 8.32% year-over-year to $50.3 million; the TTM figure through Mar 2026 stood at $50.3 million (up 8.32% YoY), while the FY2025 annual figure was $59.7 million, up 8.76% from the prior year.
• Cash & Equivalents was $50.3 million for Q1 2026 at Profound Medical, down from $59.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $59.7 million in Q4 2025 to a low of $24.8 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $43.0 million across 5 years, with a median of $46.5 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents sank 43.65% in 2023, then surged 109.48% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $46.5 million in 2022, then plunged by 43.65% to $26.2 million in 2023, then jumped by 109.48% to $54.9 million in 2024, then climbed by 8.76% to $59.7 million in 2025, then declined by 15.79% to $50.3 million in 2026.
• The last three Cash & Equivalents figures came in at $50.3 million (Q1 2026), $59.7 million (Q4 2025), and $24.8 million (Q3 2025), per Business Quant data.